Close Menu
New York Examiner News

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Roseanne Barrs Ex-Husband Makes Shocking Sex Admission

    November 15, 2026

    Shane Gillis Says He Promised SNL His Monologue Would Have No Controversy

    November 14, 2026

    Fatherland, La Bola Negra, Fjord Lead European Film Award Nominations

    November 14, 2026
    Facebook X (Twitter) Instagram
    New York Examiner News
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • Lifestyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Terms and Conditions
      • Privacy Policy
    New York Examiner News
    Home»Science»A Startup Has Unlocked a Way to Make Cheap Insulin
    Science

    A Startup Has Unlocked a Way to Make Cheap Insulin

    By AdminFebruary 6, 2024
    Facebook Twitter Pinterest LinkedIn WhatsApp Email Reddit Telegram
    A Startup Has Unlocked a Way to Make Cheap Insulin

    [ad_1]

    Now some key patents have expired, and the US Food and Drug Administration (FDA) has paved the way for biosimilar versions of insulin—so-called because they’re almost identical to another product already on the market. For a product to be biosimilar, it must be highly similar in structure to the original and work just as well in patients.

    Owen’s company, founded in 2020, has designed supercharged E. coli-like bacteria that can produce much greater amounts of insulin than existing strains used in insulin production. To do that, the company struck up a collaboration with Sergej Djuranovic, a professor of cell biology and physiology at Washington University School of Medicine in St. Louis. In 2019, Djuranovic’s lab discovered a sequence of amino acids—the building blocks of proteins—that could make a gene produce far more proteins than is usual. He and his colleagues found that the sequence worked in bacterial, yeast, and even human cells.

    “This sequence of certain amino acids will boost up protein production, and it’s purely because the protein is being made more efficiently,” Djuranovic says.

    In theory, the sequence could be used to pump out large amounts of any protein, including insulin. Being able to produce insulin more efficiently is why rBIO thinks it can drive the cost down.

    A 2018 study estimated that it costs roughly $2 to $4 to produce a vial of synthetic insulin. Owen says rBIO can do it even more cheaply, since its process yields more of the drug.

    “New technologies that will make it even less expensive are certainly good, but they’re not going to be huge game changers right away,” says Robert Lash, a diabetes expert and chief medical officer of the Washington, DC-based Endocrine Society. Ultimately, he thinks more competition will be better for patients. “The more companies that are making insulin and the more options patients have available, the less expensive it’s going to become over time,” he says.

    Even with the FDA’s blessing, few players outside the big three insulin manufacturers have broken into the market. In July 2021, the drug Semglee from Mylan Pharmaceuticals and Biocon Biologics became the first biosimilar insulin approved by the FDA, as an interchangeable product for Sanofi’s Lantus insulin. Later that year, the agency approved Rezvoglar by Eli Lilly as a biosimilar for Lantus, made by Sanofi. The three major insulin makers have also come out with unbranded versions of their own brand-name insulins.

    Utah-based Civica, a nonprofit pharma company, announced plans in 2022 to manufacture and distribute its own low-cost insulin, pledging to cap prices at $30 per vial and $55 for a box of five cartridges. Last year, California entered into a contract with Civica so that the state could produce its own affordable insulin.

    Owen says rBIO is aiming to reduce the cost of insulin by 30 percent. Its product, R-biolin, is designed to be a copy of Novo Nordisk’s Novolin, a fast-acting insulin that starts working within 30 minutes and lasts for 8 hours. This month, Novo Nordisk lowered the list price for several of its branded and unbranded insulins, including Novolin. It now charges $48.20 for a vial and $91.09 for a FlexPen of Novolin.

    The Houston startup still has to prove whether its insulin works as well as Novolin, and even then, rBIO will have little control over the price patients end up paying. Like other manufacturers, rBIO would sell its insulin to pharmacy benefit managers. “We still think we can lower the cost significantly,” Owen says.

    Updated 4-19-2022 5:00 pm ET: The onset time and length of duration of Novo Nordisk’s Novolin was corrected.

    [ad_2]

    Original Source Link

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Email Reddit Telegram
    Previous Article2023 Dorian Film Awards Full List of Nominations – The Hollywood Reporter
    Next Article Apple brings enterprise device management to the Vision Pro

    RELATED POSTS

    Climate Change Has Pushed the World's Ice Out of Its Safe Zone

    November 12, 2026

    Synchron Pauses Trials of Its Brain Implant Due to Performance Issues

    November 12, 2026

    The Polar Vortex Is About to Make Weather Weird From the UK to the US

    November 12, 2026

    A Startup Wants to Fight AI Bioweapons With AI

    November 11, 2026

    Michigan Residents Voted to Get Corporate Money Out of Politics. Now Utilities Are Suing

    November 11, 2026

    Chatbots Are Leading Hikers Astray, With Dangerous Consequences

    November 1, 2026
    latest posts

    Roseanne Barrs Ex-Husband Makes Shocking Sex Admission

    Roseanne Barr recently revealed plans for a comeback eight years after she was “canceled.” The…

    Shane Gillis Says He Promised SNL His Monologue Would Have No Controversy

    November 14, 2026

    Fatherland, La Bola Negra, Fjord Lead European Film Award Nominations

    November 14, 2026

    Journey Drummer Deen Castronovo Exits Mid-Tour to Focus on His Health

    November 14, 2026

    3 Best Movies To Watch On HBO Max This Weekend ($1 Is Sydney Sweeneys $100 Million Sci-Fi Thriller)

    November 14, 2026

    Happys Place: Reba McEntire Teases Whats Next for Bobbie & JB

    November 14, 2026

    Amazons new Kindle Colorsoft is a premium e-reader with a premium price | TechCrunch

    November 14, 2026
    Categories
    • Books (1,588)
    • Business (6,481)
    • Events (85)
    • Film (6,447)
    • Lifestyle (4,500)
    • Music (6,580)
    • Politics (6,447)
    • Science (5,848)
    • Technology (6,435)
    • Television (6,140)
    • US News (6,484)
    popular posts

    Hackers access DoorDash data, T-Mobile teams up with SpaceX, and eBay buys TCGplayer – TechCrunch

    [ad_1] Hello, hello! We’re back with another edition of Week in Review, the newsletter where…

    Better Call Saul Supports The Best Kim Ending Theory

    May 21, 2022

    Sony raises price of PlayStation 5 console due to soaring inflation

    August 25, 2022

    Mistrial Declared in Lindsay Clancy Case

    September 4, 2026
    Archives
    Browse By Category
    • Books (1,588)
    • Business (6,481)
    • Events (85)
    • Film (6,447)
    • Lifestyle (4,500)
    • Music (6,580)
    • Politics (6,447)
    • Science (5,848)
    • Technology (6,435)
    • Television (6,140)
    • US News (6,484)
    About Us

    We are a creativity led international team with a digital soul. Our work is a custom built by the storytellers and strategists with a flair for exploiting the latest advancements in media and technology.

    Most of all, we stand behind our ideas and believe in creativity as the most powerful force in business.

    What makes us Different

    We care. We collaborate. We do great work. And we do it with a smile, because we’re pretty damn excited to do what we do. If you would like details on what else we can do visit out Contact page.

    Our Picks

    Happys Place: Reba McEntire Teases Whats Next for Bobbie & JB

    November 14, 2026

    Amazons new Kindle Colorsoft is a premium e-reader with a premium price | TechCrunch

    November 14, 2026

    Rosalía makes history with Album Of The Year award win at Latin Grammys and performs Lux medley

    November 13, 2026
    © 2026 New York Examiner News. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms & Conditions and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT